COVID-19-associated central retinal vein occlusion treated with oral aspirin
暂无分享,去创建一个
[1] Covid-2019-vaccine-biological-e.-limited , 2023, Reactions Weekly.
[2] S. Natarajan,et al. Central retinal vein occlusion with COVID-19 infection as the presumptive etiology , 2020, Indian journal of ophthalmology.
[3] R. Narayanan,et al. Retinal vein occlusion in COVID-19: A novel entity , 2020, Indian journal of ophthalmology.
[4] M. Luppi,et al. COVID-19, coagulopathy and venous thromboembolism: more questions than answers , 2020, Internal and Emergency Medicine.
[5] R. Brodsky,et al. Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily , 2020, British journal of haematology.
[6] G. Grasselli,et al. Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.
[7] Xiaowei Yan,et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.
[8] D. Do,et al. Management of macular edema due to central retinal vein occlusion – The role of aflibercept , 2017, Taiwan journal of ophthalmology.
[9] J. Vane,et al. The mechanism of action of aspirin. , 2003, Thrombosis research.
[10] L. Hansen,et al. The natural course of central retinal vein occlusion. , 1991, American journal of ophthalmology.